
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Clinical Cancer Research, Vol 3, Issue 4 601-604, Copyright © 1997 by American Association for Cancer Research
ARTICLES |
M Younes and R Laucirica
Departments of Pathology, Baylor College of Medicine and the Methodist Hospital, Houston, Texas 77030, USA.
Histological grade (HG), as modified by Elston and Ellis (Histopathology, 19: 403-410, 1991), was shown to be a significant prognostic indicator in a large group of women with invasive breast cancer, who had node-negative as well as node-positive tumors and included special types of breast cancer. The aim of this study was to determine the utility of HG as a prognostic indicator in node-negative invasive breast cancer, no special type (NN-BCA-NST), which represents the majority of cases seen in clinical practice. One hundred eighty-two women with NN-BCA-NST and who had 28-106 months follow-up (mean, 73 months; median, 71 months) were entered in the study. Bilateral and multifocal cancers, and cancers with distant metastases, were excluded. Nuclear grade (NG), tubule formation (TF), mitotic index (MI), and HG were determined and scored as described by Elston and Ellis (Histopathology, 19: 403-410, 1991). Survival analysis was performed by the Kaplan-Meier method and the log-rank test. Regression analysis was used to determine the relationship between NG, TF, and MI. There was significant correlation between NG and MI (R = 0.667, P < 0.0001) and between TF and MI (R = 0.416, P < 0.0001). NG, TF, MI, and HG did not have significant prognostic value (P = 0.3771, P = 0.7972, P = 0.2953, and P = 0.7946, respectively). HG was of no significant prognostic value even after women who received adjuvant therapy were excluded from the analysis (P = 0.3917). Our data show that the HG is not a reliable prognostic indicator in NN-BCA-NST.
This article has been cited by other articles:
![]() |
A. V. Ivshina, J. George, O. Senko, B. Mow, T. C. Putti, J. Smeds, T. Lindahl, Y. Pawitan, P. Hall, H. Nordgren, et al. Genetic Reclassification of Histologic Grade Delineates New Clinical Subtypes of Breast Cancer Cancer Res., November 1, 2006; 66(21): 10292 - 10301. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Colleoni, N. Rotmensz, C. Robertson, L. Orlando, G. Viale, G. Renne, A. Luini, P. Veronesi, M. Intra, R. Orecchia, et al. Very young women (<35 years) with operable breast cancer: features of disease at presentation Ann. Onc., February 20, 2002; 13(2): 273 - 279. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Lundin, M. Lundin, K. Holli, V. Kataja, L. Elomaa, L. Pylkkanen, T. Turpeenniemi-Hujanen, and H. Joensuu Omission of Histologic Grading From Clinical Decision Making May Result in Overuse of Adjuvant Therapies in Breast Cancer: Results From a Nationwide Study J. Clin. Oncol., January 1, 2001; 19(1): 28 - 36. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |